Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
Porton Pharma Solutions Ltd. caters to pharmaceutical companies by manufacturing and supplying a diverse portfolio of products, which encompasses small molecule active pharmaceutical ingredients (APIs), drug intermediates, various dosage forms, and biologics. The company was formerly known as Porton Fine Chemicals Ltd. until it adopted its current name in January 2018. Established in 2005, Porton Pharma Solutions Ltd. operates from its headquarters in Chongqing, China.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA, reasonably priced on P/FC.
Target Price
The average target price of 300363.SZ is 30.0 and suggests 41.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to